Equitage Ventures

Equitage Ventures is a Denver-based early-stage firm with a healthcare thesis centered on care delivery and tech-enabled services, the parts of the system where physical operations and software meet. The firm writes $1M-$5M checks across pre-seed, seed, and Series A and tends to back founders who are willing to operate the messier parts of healthcare rather than build pure software around them. That bias defines the firm’s posture and the kinds of conversations founders should expect.

The declared sub-verticals are care delivery and tech-enabled services, plus broader digital health, with an AI lens. In practice that means interest in tech-enabled clinical operations, specialty care models, virtual and hybrid care delivery, value-based care enablement, and AI tooling that improves the unit economics of care delivery businesses. The firm is generally less drawn to pure consumer wellness, to therapeutics, or to thin software wrappers without operational ambition. The strongest fits are companies that are willing to take operational responsibility and use software and AI as a leverage point rather than the entire product.

Check sizes of $1M-$5M let Equitage operate as a lead or co-lead in early rounds and follow on selectively as companies progress. Geographically the focus is the US, with particular density in Mountain West companies and openness to coastal companies that want a regional investor with care-delivery fluency. The firm has built relationships with operators and clinical partners that matter when companies need to recruit clinical leadership, structure provider networks, or work through reimbursement strategy.

The team is small and senior, with operator and investor backgrounds that translate into practical diligence rather than process-heavy fund machinery. Founders should expect direct conversations about clinical model, unit economics, payer mix, and the operational realities of running a tech-enabled care delivery business. The diligence style tends to be more grounded in operating questions than in pure software metrics, which suits the kind of company the firm targets.

For founders, the practical read is that Equitage is a credible early-stage partner for tech-enabled healthcare services companies, particularly those willing to operate clinical or operational parts of the value chain. It is less useful for therapeutics, for pure consumer plays, or for founders who want a generalist tech investor with no healthcare specialty. The engagement style is hands-on and operationally engaged, with real time spent on clinical model design, payer strategy, and the move from early traction to scaled operations. Founders building tech-enabled care delivery companies and looking for a Mountain West-anchored partner with serious operational fluency will find Equitage a sensible early-stage choice and should pitch on the operational thesis rather than the software narrative.